Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity, today announced that management will be participating in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8 at 12:50pm ET.

A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.

Contacts for Terns

InvestorsJustin Nginvestors@ternspharma.com

MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com

 

Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Terns Pharmaceuticals Charts.
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Terns Pharmaceuticals Charts.